166 related articles for article (PubMed ID: 12200700)
1. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
[TBL] [Abstract][Full Text] [Related]
3. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
Mayorga J; Richardson-Hardin C; Dicke KA
Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
6. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
7. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
8. Arsenicals in hematologic cancers.
Novick SC; Warrell RP
Semin Oncol; 2000 Oct; 27(5):495-501. PubMed ID: 11049017
[TBL] [Abstract][Full Text] [Related]
9. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.
Berenson JR; Yeh HS
Clin Lymphoma Myeloma; 2006 Nov; 7(3):192-8. PubMed ID: 17229334
[TBL] [Abstract][Full Text] [Related]
10. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
11. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients.
Rousselot P; Larghero J; Arnulf B; Poupon J; Royer B; Tibi A; Madelaine-Chambrin I; Cimerman P; Chevret S; Hermine O; Dombret H; Claude Brouet J; Paul Fermand J
Leukemia; 2004 Sep; 18(9):1518-21. PubMed ID: 15269785
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R
Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study.
Sanaat Z; Rezazadeh M; Gharamaleki JV; Ziae JE; Esfahani A
Acta Med Iran; 2011; 49(8):504-8. PubMed ID: 22009804
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide: an ancient drug revived.
Zhou J
Chin Med J (Engl); 2012 Oct; 125(19):3556-60. PubMed ID: 23044323
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
Bajorin DF; Halabi S; Small E
Clin Genitourin Cancer; 2009 Oct; 7(3):E66-70. PubMed ID: 19815484
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
